LAVA Therapeutics (NASDAQ:LVTX – Get Rating) – Equities researchers at Jefferies Financial Group upped their FY2023 EPS estimates for LAVA Therapeutics in a research note issued on Thursday, November 17th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will earn ($1.97) per share for the year, up from their previous estimate of ($2.07). The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($0.87) per share. Jefferies Financial Group also issued estimates for LAVA Therapeutics’ FY2024 earnings at ($1.75) EPS, FY2025 earnings at ($1.99) EPS and FY2026 earnings at ($1.63) EPS.
Other analysts also recently issued research reports about the stock. JMP Securities started coverage on shares of LAVA Therapeutics in a report on Thursday, September 15th. They set an “outperform” rating on the stock. HC Wainwright initiated coverage on shares of LAVA Therapeutics in a report on Tuesday, October 25th. They set a “buy” rating and a $9.00 price objective for the company. Finally, SVB Leerink lifted their price objective on shares of LAVA Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 27th.
LAVA Therapeutics Stock Up 6.7 %
LAVA Therapeutics (NASDAQ:LVTX – Get Rating) last announced its quarterly earnings data on Tuesday, September 13th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.30. The company had revenue of $0.47 million during the quarter, compared to analyst estimates of $1.00 million. LAVA Therapeutics had a negative net margin of 154.15% and a negative return on equity of 26.44%.
Institutional Investors Weigh In On LAVA Therapeutics
A hedge fund recently bought a new stake in LAVA Therapeutics stock. UBS Oconnor LLC acquired a new stake in LAVA Therapeutics (NASDAQ:LVTX – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 75,000 shares of the company’s stock, valued at approximately $343,000. UBS Oconnor LLC owned 0.30% of LAVA Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.92% of the company’s stock.
About LAVA Therapeutics
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
- Get a free copy of the StockNews.com research report on LAVA Therapeutics (LVTX)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.